Clinical Trials

Phase 1 Active not recruiting

Lung Neoplasms

NCT04837716 2026-02-19

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

12 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07354061 2026-01-21

TD-ENSEMBLE

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07235306 2025-11-19

Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC

45 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02767804 2025-10-14

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

290 enrolled 1 FDA

Phase 4 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06785584 2025-01-21

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

30 enrolled

ALK-positive Advanced NSCLC

NCT06779539 2025-01-17

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06780839 2025-01-17

Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06563999 2024-12-10

NUMER

Phase 2 Recruiting

120 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05491811 2024-09-19

EAGLE

49 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05341583 2024-08-23

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Phase 3 Recruiting

202 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05241028 2023-10-10

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Phase 2 Recruiting

80 enrolled

Other solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung

NCT02959619 2023-08-21

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Phase 1 Completed

48 enrolled

Solid Tumor

NCT03215693 2023-08-16

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

152 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03574402 2022-12-06

TRUMP

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02898116 2022-10-10

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Phase 1/2 Completed

2 enrolled 8 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05186506 2022-01-11

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

152 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05178511 2022-01-05

ERSGATR

40 enrolled

The Diagnosis Was ALK Positive NSCLC

NCT01625234 2021-10-06

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Phase 1/2 Completed

131 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04415320 2020-06-04

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

37 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03510611 2019-07-24

A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.

Phase 1 Completed

24 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03536481 2019-07-24

Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers

Phase 1 Completed

74 enrolled